|
[1]
|
M. E. Cockman, N. Masson, D. R. Mole, P. Jaakkola, G. W. Chang, S. C. Clifford, E. R. Maher, C. W. Pugh, P. J. Ratcliffe and P. H. Maxwell, “Hypoxia Inducible Factor-Alpha Binding and Ubiquitylation by the Von Hippel-Lindau Tumor Suppressor Protein,” Journal of Biological Chemistry, Vol. 275, No. 33, 2000, pp. 25733-25741. doi:10.1074/jbc.M002740200
|
|
[2]
|
D. W. Kim, Y. S. Jo, H. S. Jung, H. K. Chung, J. H. Song, K. C. Park, S. H. Park, J. H. Hwang, S. Y. Rha, G. R. Kweon, S. J. Lee, K. W. Jo and M. Shong, “An Orally Administered Multitarget Tyrosine Kinase Inhibitor, SU11248, Is a Novel Potent Inhibitor of Thyroid Oncogenic RET/Papillary Thyroid Cancer Kinases,” Journal of Clinical Endocrinology & Metabolism, Vol. 91, No. 10, 2006, pp. 4070-4076. doi:10.1210/jc.2005-2845
|
|
[3]
|
W. Y. Kim and W. G. Kaelin, “Role of VHL Gene Mutation in Human Cancer,” Journal of Clinical Oncology, Vol. 22, No, 24, 2004, pp. 4991-5004.
doi:10.1200/JCO.2004.05.061
|
|
[4]
|
K. J. Gotink and H. M. W. Verheul, “Anti-Angiogenic Tyrosine Kinase Inhibitors: What Is Their Mechanism of Action?” Angiogenesis, Vol. 13, No. 1, 2010, pp. 1-14.
doi:10.1007/s10456-009-9160-6
|
|
[5]
|
R. H. Gunby, E. Sala, C. J. Tartari, M. Puttini, C. Gambacorti-Passerini and L. Mologni, “Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy,” Anti-Cancer Agents in Medicinal Chemistry, Vol. 7, No. 6, 2007, pp. 594-611.
doi:10.2174/187152007784111340
|
|
[6]
|
T. J. Abrams, L. J. Murray, E. Pesenti, V. W. Holway, T. Colombo, L. B. Lee, J. M. Cherrington and N. K. Pryer, “Preclinical Evaluation of the Tyrosine Kinase Inhibitor SU11248 as a Single Agent and in Combination with “Standard of Care” Therapeutic Agents for the Treatment of Breast Cancer,” Molecular Cancer Therapeutics, Vol. 2, No. 10, 2003, pp. 1011-1021.
|
|
[7]
|
D. W. Kim, Y. S. Jo, H. S. Jung, H. K. Chung, J. H. Song, K. C. Park, S. H. Park, J. H. Hwang, S. Y. Rha, G. R. Kweon, S. J. Lee, K. W. Jo and M. Shong, “An Orally Administered Multitarget Tyrosine Kinase Inhibitor, SU-11248, Is a Novel Potent Inhibitor of Thyroid Oncogenic RET/Papillary Thyroid Cancer Kinases,” Clinical Endocrinology & Metabolism, Vol. 91, No. 10, 2006, pp. 4070-4076. doi:10.1210/jc.2005-2845
|
|
[8]
|
D. B. Mendel, A. D. Laird, X. Xin, S. G. Louie, J. G. Christensen, et al, “In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship,” Clinical Cancer Research, Vol. 9, No.1, 2003, pp. 327-337.
|
|
[9]
|
D. J. Hicklin and L. M. Ellis, “Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis,” Journal of Clinical Oncology, Vol. 23, No. 5, 2005, pp. 1011-1027.
|
|
[10]
|
U. McDermott, R. Y. Ames, A. J. Iafrate, S. Maheswaran, H. Stubbs, P. Greninger, K. McCutcheon, R. Milano, S. Y. Rha, A. Tam, D. Y. Lee, L. Lucien, B. W. Brannigan, L. E. Ulkus, X. J. Ma, M. G. Erlander, D. A. Haber, S. V. Sharma and J. Settleman, “Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-Alpha Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors,” Cancer Research, Vol. 69, No. 9, 2009, pp. 3937-3946.
doi:10.1158/0008-5472.CAN-08-4327
|
|
[11]
|
J. O. Haznedar, S. Patyna, C. L. Bello, G. W. Peng, W. Speed, X. Yu, Q. Zhang, J. Sukbuntherng, D. J. Sweeny, L. Antonian and E. Y. Wu, “Single- and Multiple-Dose Disposition Kinetics of Sunitinib Malate, a Multitargeted Receptor Tyrosine Kinase Inhibitor: Comparative Plasma Kinetics in Non-Clinical Species,” Cancer Chemotherapy & Pharmacology, Vol. 64, No. 4, 2009, pp. 691-706.
doi:10.1007/s00280-008-0917-1
|
|
[12]
|
H. Xin, C. Zhang, A. Herrmann, Y. Du, R. Figlin and H. Yu, “Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells,” Cancer Research, Vol. 69, No. 6, 2009, pp. 2506-2513. doi:10.1158/0008-5472.CAN-08-4323
|
|
[13]
|
B. Barré, A. Vigneron, N. Perkins, I. B. Roninson, E. Gamelin and O. Coqueret, “The STAT3 Oncogene as a Predictive Marker of Drug Resistance,” Trends in Molecular Medicine, Vol. 13, No. 1, 2007, pp. 4-11.
doi:10.1016/j.molmed.2006.11.001
|
|
[14]
|
N. P. van Erp, K. Eechoute, A. A. van der Veldt, J. B. Haanen, A. K. Reyners, R. H. Mathijssen, E. Boven, T. van der Straaten, R. F. Baak-Pablo, J. A. Wessels, H. J. Guchelaar and H. Gelderblom, “Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity,” Journal of Clinical Oncology, Vol. 27, No. 26, 2009, pp. 4406-4412. doi:10.1200/JCO.2008.21.7679
|
|
[15]
|
C. L. Bello, L. Sherman, J. Zhou, L. Verkh, J. Smeraglia, J. Mount and K. J. Klamerus, “Effect of Food on the Pharmacokinetics of Sunitinib Malate (SU11248), a Multi-targeted Receptor Tyrosine Kinase Inhibitor: Results from a Phase I Study in Healthy Subjects,” Anticancer Drugs, Vol. 17, No. 3, 2006, pp. 353-358.
doi:10.1097/00001813-200603000-00015
|
|
[16]
|
SUTENT (Sunitinib Malate) Prescribing Information, New York, Pfizer Labs.
|
|
[17]
|
V. L. Goodman, E. P. Rock, R. Dagher, R. P. Ramchandani, S. Abraham, J. V. Gobburu, B. P. Booth, S. L. Verbois, D. E. Morse, C. Y. Liang, N. Chidambaram, J. X. Jiang, S. Tang, K. Mahjoob, R. Justice and R. Pazdur, “Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma,” Clinical Cancer Research, Vol. 13, No. 5, 2007, pp. 1367-1373.
doi:10.1158/1078-0432.CCR-06-2328
|
|
[18]
|
V. R. Adams and M. Leggas, “Sunitinib Malate for the Treatment of Metastatic Renal Cell Carcinoma and Gastrointestinal Stromal Tumors,” Clinical Therapeutics, Vol. 29, No. 7, 2007, pp. 1338-1353.
doi:10.1016/j.clinthera.2007.07.022
|
|
[19]
|
Pfizer Labs, Division of Pfizer Inc New York, 2010.
|
|
[20]
|
B. E. Houk, C. L. Bello, D. Kang and M. Amantea, “A Population Pharmacokinetic Meta-Analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients,” Clinical Cancer Research, Vol. 15, No. 7, 2009, pp. 2497-2506.
doi:10.1158/1078-0432.CCR-08-1893
|
|
[21]
|
K. M. Sakamoto, “Su-11248 Sugen,” Current Opinion in Investigational Drugs, Vol. 5, No. 12, 2004, pp. 1329-1339.
|
|
[22]
|
N. P. van Erp, S. D. Baker, A. S. Zandvliet, B. A. Ploeger, M. den Hollander, Z. Chen, J. den Hartigh, J. M. Konig-Quartel, H. J. Guchelaar and H. Gelderblom, “Marginal Increase of Sunitinib Exposure by Grapefruit Juice,” Cancer Chemotherapy and Pharmacology, Vol. 67, No. 3, 2010, pp. 695-703.
doi:10.1007/s00280-010-1367-0
|
|
[23]
|
A. Italiano and B. Bui, “Gastrointestinal Stromal Tumors: Molecular Aspects and Therapeutic Implications,” Bull Cancer, Vol. 95, No. 1, 2008, pp. 107-116.
|
|
[24]
|
T. Nishida, “Imatinib. Sunitinib,” Gan To Kagaku Ryoho, Vol. 34, 2007, pp. 1196-1200.
|
|
[25]
|
J. O. Lee, K. W. Lee, C. J. Kim, Y. J. Kim, H. E. Lee, H. Kim, J. H. Kim, S. M. Bang, J. S. Kim and J. S. Lee, “Metastatic Adrenocortical Carcinoma Treated with Sunitinib: A Case Report” Japanese Journal of Clinical Oncology, Vol. 39,No. 8, 2009, pp. 183-185.
|
|
[26]
|
M. Palmowski, J. Huppert, P. Hauff, M. Reinhardt, K. Schreiner, M. A. Socher, P. Hallscheidt, G. Kauffmann, W. Semmler and F. Kiessling, “Vessel Fractions in Tumor Xenografts Depicted by Flow- or Contrast-Sensitive Three-Dimensional High-Frequency Doppler Ultrasound Respond Differently to Antiangiogenic Treatment,” Cancer Research, Vol. 68, No. 17, 2008, pp. 7042-7049.
doi:10.1158/0008-5472.CAN-08-0285
|
|
[27]
|
C. L. Dai, Y. J. Liang, Y. S. Wang, A. K. Tiwari, Y. Y. Yan, F. Wang, Z. S. Chen, X. Z. Tong and L. W. Fu, “Sensitization of ABCG2-Overexpressing Cells to Conventional Chemotherapeutic Agent by Sunitinib Was Associated with Inhibiting the Function of ABCG2,” Cancer Letters, Vol. 279, No. 1, 2009, pp. 74-83.
doi:10.1016/j.canlet.2009.01.027
|
|
[28]
|
C. J. Sweeney, E. G. Chiorean, C. F. Verschraegen, F. C. Lee, S. Jones, M. Royce, L. Tye, K. F. Liau, A. Bello, R. Chao and H. A. Burris, “A Phase I Study of Sunitinib Plus Capecitabine in Patients with Advanced Solid Tumors,” Journal of Clinical Oncology, Vol. 28, No. 28, 2010, pp. 4513-4520. doi:10.1200/JCO.2009.26.9696
|
|
[29]
|
E. Boven, C. Massard, J. P. Armand, C. Tillier, V. Hartog, N. M. Brega, A. M. Countouriotis, A. Ruiz-Garcia and J. C. Soria, “A Phase I, Dose-Finding Study of Sunitinib In Combination with Irinotecan in Patients with Advanced Solid Tumours,” British Journal of Cancer, Vol. 103, No. 7, 2010, pp. 993-1000. doi:10.1038/sj.bjc.6605852
|
|
[30]
|
N. Suhail, N. Bilal, H. Y. Khan, S. Hasan, S. Sharma, F. Khan, T. Mansoor and N. Banu, “Effect of Vitamins C and E on Antioxidant Status of Breast-Cancer Patients Undergoing Chemotherapy,” Journal of Clinical Pharmacy and Therapeutics, 2011, Online Version of Record Published before Inclusion in an Issue.
doi:10.1111/j.1365-2710.2010.01237.x
|
|
[31]
|
K. Tikoo, M. S. Sane and C. Gupta, “Tannic Acid Ameliorates Doxorubicin-Induced Cardiotoxicity and Potentiates Its Anti-Cancer Activity: Potential Role of Tannins in Cancer Chemotherapy,” Toxicology and Applied Pharmacology, Vol. 251, No. 3, 2011, pp. 191-200.
doi:10.1016/j.taap.2010.12.012
|
|
[32]
|
D. Huang, Y. Ding, M. Zhou, B. I. Rini, D. Petillo, C. N. Qian, R. Kahnoski, P. A. Futreal, K. A. Furge and B. T. Teh, “Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma,” Cancer Research, Vol. 70, No. 3, 2010, pp. 1063-1071.
doi:10.1158/0008-5472.CAN-09-3965
|
|
[33]
|
G. Bergers and D. Hanahan, “Modes of Resistance to Anti-Angiogenic Therapy,” Nature Reviews Cancer, Vol. 8, No. 8, 2008, pp. 592-603. doi:10.1038/nrc2442
|
|
[34]
|
S. Charles, M. L. James, M. Gerlinger., C. E. Aron, H. Michael, S. Gordon, D. Julian, M. Gore., F. P. Andrew, E. Bernard, A. Fabrice, A. Laurence, B. Benoit, O. Stephane, H. Jens, G. Balázs, J. T. Chris, A. B. Karen, V. Hansjuergen, T. Luisella, N. Barbara, B. Marlene and S. Zoltan, “Predictive Biomarker Discovery Through the Parallel Integration of Clinical Trial and Functional Genomics Datasets,” Genome Medicine, Vol. 2, No. 8, 2010, p. 53.
doi:10.1186/gm174
|
|
[35]
|
F. Shojaei, J. H. Lee, B. H. Simmons, A. Wong, C. O. Esparza, P. A. Plumlee, J. Feng, A. E. Stewart, D. D. Hu- Lowe and J. G. Christensen, “HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors,” Cancer Research, Vol. 70, No. 24, 2010, pp. 10090-10100. doi:10.1158/0008-5472.CAN-10-0489
|
|
[36]
|
H. J. Hammers, H. M. Verheul, B. Salumbides, R. Sharma, M. Rudek, J. Jaspers, P. Shah, L. Ellis, L. Shen, S. Paesante, K. Dykema, K. Furge, B. T. Teh, G. Netto and R. Pili, “Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study,” Molecular Cancer Therapeutics, Vol. 9, No. 6, 2010, pp. 1525-1535.
|
|
[37]
|
A. Dahan, H. Sabit and G. L. Amidon, “The H2 Receptor Antagonist Nizatidine Is a P-Glycoprotein Substrate: Characterization of Its Intestinal Epithelial Cell Efflux Transport,” AAPS Journal, Vol. 11, No. 2, 2009, pp. 205- 213. doi:10.1208/s12248-009-9092-5
|
|
[38]
|
L. Z. Benet, T. Izumi, Y. Zhang, J. A. Silverman, V. J. Wacher, “Intestinal MDR Transport Proteins and P-450 Enzymes as Barriers to Oral Drug Delivery,” Journal of Controlled Release, Vol. 62. No. 1, 1999, pp. 25-31.
doi:10.1016/S0168-3659(99)00034-6
|
|
[39]
|
V. J. Wacher, J. A. Silverman, Y. Zhang and L. Z. Benet, “Role of P-Glycoprotein and Cytochrome P450 3A in Limiting Oral Absorption of Peptides and Peptidomimetics,” Journal of Pharmaceutical Sciences, Vol. 87, No. 11, 1998, pp. 1322-1330. doi:10.1021/js980082d
|
|
[40]
|
M. Ceckova-Novotna, P. Pavek and F. Staud, “P-Glycoprotein in the Placenta: Expression, Localization, Regulation and Function,” Reproductive Toxicology, Vol. 22, No. 3, 2006, pp. 400-410. doi:10.1016/j.reprotox.2006.01.007
|
|
[41]
|
H. Sugimoto, H. Hirabayashi, Y. Kimura, A. Furuta, N. Amano and T. Moriwaki, “Quantitative Investigation of the Impact of P-Glycoprotein Inhibition on Drug Transport across Blood-Brain Barrier in Rats,” Drug Metabolism and Disposition, Vol. 39, No. 1, 2010, pp. 8-14.
doi:10.1124/dmd.110.035774
|
|
[42]
|
A. Dahan and H. Altman, “Food-Drug Interaction: Grapefruit Juice Augments Drug Bioavailability—Mechanism, Extent and Relevance,” European Journal of Clinical Nutrition, Vol. 58, No. 1, 2004, pp. 1-9.
doi:10.1038/sj.ejcn.1601736
|
|
[43]
|
L. Z. Benet, C. L. Cummins and C. Y. Wu, “Transporter-Enzyme Interactions: Implications for Predicting Drug-Drug Interactions from in Vitro Data,” Current Drug Metabolism, Vol. 4, No. 5, 2003, pp. 393-398.
doi:10.2174/1389200033489389
|
|
[44]
|
M. Takano, R. Yumoto and T. Murakami, “Expression and Function of Efflux Drug Transporters in the Intestine,” Pharmacology & Therapeutics, Vol. 109, No. 1-2, 2006, pp. 137-161. doi:10.1016/j.pharmthera.2005.06.005
|